Thiazolopyridine Derivatives for Selective A2A/A2B Antagonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current adenosine A2A and A2B receptor antagonists are limited in their ability to effectively treat hyperproliferative diseases such as cancer and infectious diseases, due to inadequate pharmacokinetic properties in relevant animal models and insufficient inhibition of immunosuppressive adenosine signaling.
Innovation Solution
Development of thiazolopyridine derivatives that act as highly selective inhibitors of the A2A and A2B adenosine receptors, while sparing A1 and A3 receptors, thereby enhancing immune responses and inhibiting tumor growth and metastasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current adenosine A2A and A2B receptor antagonists are used, then adenosine signaling inhibition is achieved, but pharmacokinetic properties are inadequate in relevant animal models
Solution Approach 1:
The patent modifies molecular parameters of adenosine receptor antagonists by introducing specific substituents (R1-R6 groups) at defined positions on the purine core structure. This systematic parameter optimization achieves improved pharmacokinetic properties including enhanced metabolic stability, altered plasma protein binding, and optimized tissue distribution while maintaining A2A/A2B receptor affinity.
2Reliability
If selective A2A and A2B receptor inhibition is achieved, then immunosuppression is prevented, but selectivity over A1 and A3 receptors must be maintained
Solution Approach 1:
The patent introduces specific substituent patterns at defined positions on the purine core structure to create localized molecular features that confer selectivity for A2A and A2B receptors over A1 and A3 receptors. The R1-R6 groups are strategically positioned to interact with unique residues in the A2A/A2B binding pockets while avoiding critical interactions required for A1/A3 binding, thereby achieving receptor subtype discrimination.
3Productivity
If T cells are rescued from adenosine-induced inhibition, then anti-tumor immune responses are enhanced, but tumor growth inhibition must be maintained
Solution Approach 1:
The patent employs adenosine receptor antagonists as molecular intermediaries that block adenosine's immunosuppressive signaling through A2A and A2B receptors on T cells and other immune cells. This intermediary action reverses adenosine-mediated T cell inhibition without directly interacting with tumor cells, thereby enhancing anti-tumor immunity while the compounds themselves maintain appropriate pharmacokinetic properties for effective tumor site delivery.
Data Source
AI summary
The invention relates to thiazolopyridine derivatives which fall under the general formula I,and the use of the compounds of the present invention for the treatment and/or prevention of hyperproliferative or infectious diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.